Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
Condition(s):Non-Hodgkin’s LymphomaLast Updated:May 16, 2018Terminated
Hide Studies Not Open or Pending
Condition(s):Non-Hodgkin’s LymphomaLast Updated:May 16, 2018Terminated
Condition(s):Lymphoma, FollicularLast Updated:July 11, 2014Completed
Condition(s):Relapsing Multiple SclerosisLast Updated:February 5, 2024Recruiting
Condition(s):Chronic Lymphocytic LeukemiaLast Updated:June 11, 2020Completed
Condition(s):Chronic Lymphocytic Leukemia (CLL)Last Updated:September 24, 2019Completed
Condition(s):Leukaemia, Lymphocytic, ChronicLast Updated:June 25, 2019Terminated
Condition(s):Lymphoma, FollicularLast Updated:March 27, 2020Terminated
Condition(s):Relapsing Multiple SclerosisLast Updated:April 29, 2022Completed
Condition(s):Multiple SclerosisLast Updated:February 29, 2024Recruiting
Condition(s):Non-Hodgkin’s LymphomaLast Updated:October 4, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.